X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Wockhardt - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs WOCKHARDT LTD. - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

WOCKHARDT LTD. 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA WOCKHARDT LTD. GLENMARK PHARMA/
WOCKHARDT LTD.
 
P/E (TTM) x 17.9 -11.6 - View Chart
P/BV x 3.2 2.3 140.9% View Chart
Dividend Yield % 0.4 1.4 26.0%  

Financials

 GLENMARK PHARMA   WOCKHARDT LTD.
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-17
WOCKHARDT LTD.
Mar-17
GLENMARK PHARMA/
WOCKHARDT LTD.
5-Yr Chart
Click to enlarge
High Rs9931,129 88.0%   
Low Rs729627 116.3%   
Sales per share (Unadj.) Rs325.5363.1 89.6%  
Earnings per share (Unadj.) Rs39.3-20.4 -192.2%  
Cash flow per share (Unadj.) Rs48.7-7.0 -697.7%  
Dividends per share (Unadj.) Rs2.0010.00 20.0%  
Dividend yield (eoy) %0.21.1 20.4%  
Book value per share (Unadj.) Rs159.2301.8 52.7%  
Shares outstanding (eoy) m282.17110.55 255.2%   
Bonus/Rights/Conversions ESOPIS-  
Price / Sales ratio x2.62.4 109.4%   
Avg P/E ratio x21.9-42.9 -51.0%  
P/CF ratio (eoy) x17.7-125.9 -14.1%  
Price / Book Value ratio x5.42.9 185.9%  
Dividend payout %5.1-48.9 -10.4%   
Avg Mkt Cap Rs m242,99197,063 250.3%   
No. of employees `00013.06.8 191.6%   
Total wages/salary Rs m16,4089,665 169.8%   
Avg. sales/employee Rs Th7,083.95,931.8 119.4%   
Avg. wages/employee Rs Th1,265.41,428.1 88.6%   
Avg. net profit/employee Rs Th855.1-334.0 -256.0%   
INCOME DATA
Net Sales Rs m91,85740,146 228.8%  
Other income Rs m3741,143 32.7%   
Total revenues Rs m92,23041,289 223.4%   
Gross profit Rs m20,367128 15,911.8%  
Depreciation Rs m2,6441,489 177.5%   
Interest Rs m2,3732,253 105.3%   
Profit before tax Rs m15,724-2,472 -636.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-8100-   
Tax Rs m3,827-211 -1,812.8%   
Profit after tax Rs m11,088-2,260 -490.5%  
Gross profit margin %22.20.3 6,954.2%  
Effective tax rate %24.38.5 284.9%   
Net profit margin %12.1-5.6 -214.4%  
BALANCE SHEET DATA
Current assets Rs m68,74646,160 148.9%   
Current liabilities Rs m27,02719,258 140.3%   
Net working cap to sales %45.467.0 67.8%  
Current ratio x2.52.4 106.1%  
Inventory Days Days85101 84.4%  
Debtors Days Days9694 101.6%  
Net fixed assets Rs m24,13240,165 60.1%   
Share capital Rs m282553 51.1%   
"Free" reserves Rs m44,64332,814 136.0%   
Net worth Rs m44,92533,367 134.6%   
Long term debt Rs m45,36331,903 142.2%   
Total assets Rs m117,63989,687 131.2%  
Interest coverage x7.6-0.1 -7,851.1%   
Debt to equity ratio x1.01.0 105.6%  
Sales to assets ratio x0.80.4 174.4%   
Return on assets %11.40 -133,277.2%  
Return on equity %24.7-6.8 -364.3%  
Return on capital %19.1-0.3 -5,711.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m56,1529,121 615.6%   
Fx outflow Rs m8,0842,133 379.0%   
Net fx Rs m48,0686,988 687.9%   
CASH FLOW
From Operations Rs m6,574-2,695 -244.0%  
From Investments Rs m-7,124-6,863 103.8%  
From Financial Activity Rs m5,43212,545 43.3%  
Net Cashflow Rs m1,9923,010 66.2%  

Share Holding

Indian Promoters % 48.3 74.5 64.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 2.3 300.0%  
FIIs % 34.4 7.7 446.8%  
ADR/GDR % 0.0 0.1 -  
Free float % 10.5 15.4 68.2%  
Shareholders   56,727 67,757 83.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   NATCO PHARMA  PANACEA BIOTECH  CADILA HEALTHCARE  ABBOTT INDIA  PLETHICO PHARMA  

Compare GLENMARK PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Share Markets Extend Gains; Energy & PSU Stocks Rally(12:30 pm)

Stock markets in India continue to trade higher taking cues from their key Asian counterparts. Sectoral indices are trading in green with stocks in the oil & gas sector.

Related Views on News

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top Five Stocks After the Karnataka Elections(The 5 Minute Wrapup)

May 16, 2018

The markets seem confused. They're neither going up nor down. What should investors do? Consider Safe Stocks. Here's the top 5 Safe Stocks in the market today.

How A Storm Destroyed Rain Industries... And a Superb Small Cap Stock I Recommend(Profit Hunter)

May 17, 2018

A mutual fund regulation could cause small cap prices to tank - If you haven't been paying attention to your small caps - now is the time to catch the opportunities that start pouring in.

Has the Indian Home Buyer Become Smarter?(Vivek Kaul's Diary)

May 17, 2018

Home loans continue to grow, despite falling sales. What explains this phenomenon?

Beware the 5th year of the Modi Regime(The Honest Truth)

May 22, 2018

2017 was a great year for the market. You were rewarded for taking excessive risk. But Ajit Dayal believes 2018 will be different. You will be rewarded for doing the opposite. Read on to know more...

Beware of Inflated Stock Market Angels(Sector Info)

May 17, 2018

The stock of Vakrangee helps us understand why it's a bad idea to chase high-flying stocks.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


May 28, 2018 02:51 PM

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 5-YR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS